Indivior (OTCMKTS:INVVY) Sets New 1-Year High at $14.90

Indivior PLC (OTCMKTS:INVVY) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $14.90 and last traded at $14.81, with a volume of 2924 shares changing hands. The stock had previously closed at $14.59.

Separately, Zacks Investment Research raised shares of Indivior from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Tuesday.

The firm’s 50-day moving average price is $12.24 and its 200-day moving average price is $10.81. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $2.16 billion, a PE ratio of 25.16 and a beta of 0.22.

About Indivior (OTCMKTS:INVVY)

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, and Sublocade Injection. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Further Reading: How is inflation measured?

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.